Pilot Study of 89-Zr Panitumumab in Pancreas Cancer

Trial ID or NCT#



not recruiting iconNOT RECRUITING


The main purpose of the study is to assess the safety of 89Zr-panitumumab as a molecular imaging agent in patients with (metastatic) pancreas cancer.

Official Title

Pilot Study of 89Zr Panitumumab in Pancreas Cancer

Eligibility Criteria

Ages Eligible for Study: Older than 19 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Confirmed diagnosis of pancreatic cancer.
Exclusion Criteria:
  1. - Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment. - History of infusion reactions to monoclonal antibody therapies. - Pregnant or breastfeeding. - Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. - Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis. - Severe renal disease or anuria. - Known hypersensitivity to deferoxamine or any of its components.


Andrei Iagaru
Andrei Iagaru
Professor of Radiology (Nuclear Medicine)
George A. Poultsides, MD, MS
George A. Poultsides, MD, MS
Hepatobiliary surgeon, Pancreatic surgeon, Liver surgeon, Sarcoma specialist, Gastrointestinal specialist, Minimally invasive surgeon
Professor of Surgery (General Surgery)
George A. Fisher Jr.
George A. Fisher Jr.
Medical oncologist, Gastrointestinal specialist
Colleen Haas Chair in the School of Medicine

Contact us to find out if this trial is right for you.


Alexander A Valencia